The initial coagulopathy of COVID-19 is characterized by increased D-dimer and fibrinogen or fibrin degradation products, as well as abnormalities in prothrombin time, acute partial thromboplastin time, and platelet counts (22). This evidence concerns the gene F2 and blood coagulation disease.